PT  - JOURNAL ARTICLE
AU  - HIRONORI YOSHIDA
AU  - YOUNG HAK KIM
AU  - HIROAKI OZASA
AU  - YUICHI SAKAMORI
AU  - TAKAHIRO TSUJI
AU  - TAKASHI NOMIZO
AU  - YUTO YASUDA
AU  - TOMOKO YAMAMOTO
AU  - HITOMI AJIMIZU
AU  - TOYOHIRO HIRAI
TI  - Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
AID  - 10.21873/invivo.11418
DP  - 2018 Nov 01
TA  - In Vivo
PG  - 1587--1590
VI  - 32
IP  - 6
4099  - http://iv.iiarjournals.org/content/32/6/1587.short
4100  - http://iv.iiarjournals.org/content/32/6/1587.full
SO  - In Vivo2018 Nov 01; 32
AB  - Background: Alectinib is a new standard treatment for treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, resistance ultimately develops in almost all patients, and data regarding the efficiency of ceritinib for such patients are insufficient. Patients and Methods: Patients with ALK-positive NSCLC treated at the Kyoto University Hospital from January 2012 to March 2017 were reviewed. Patients who were treated with ceritinib after alectinib were identified, and the efficacy of ceritinib after alectinib was retrospectively evaluated. Results: There were 35 patients with ALK-positive NSCLC, nine of whom received ceritinib after alectinib. The overall response rate to ceritinib was 44%. It was 16% in patients who received ceritinib immediately after alectinib, and 100% in patients who received chemotherapy before ceritinib. The median progression-free survival for patients treated with ceritinib was 4.4 months (95% confidence interval(CI)=1.1-6.5 months). Conclusion: Ceritinib demonstrated a modest clinical benefit after failure of alectinib. Ceritinib may be a reasonable treatment option in this setting.